Malaria,FalciparumNCT05567016
CHILD (Child Health and Infection With Low Density) Malaria
A study testing Active case detection using molecular testing (ACDm) and Passive case detection using molecular testing (PCDm) in people with Malaria,Falciparum and Malaria, run by University of California, San Francisco at 1 site in Tanzania.
Trial summary
This trial will assess the long-term health and socioeconomic impact of interventions targeting low-density malaria infection (LMI) among children in Tanzania Read more about this study
- Who is it for?
- Ages 6 months to 10 yearsHealthy volunteers can take part
- Conditions the study is for
- Malaria,Falciparum, Malaria
- What is being tested?
- Active case detection using molecular testing (ACDm) and Passive case detection using molecular testing (PCDm)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 600 participants
- Where
- 1 siteTanzania
- Study dates
- 18 Jul 2023to 28 Nov 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 months to 10 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- 6 months to 10 years of age of age at enrollment
- Primary residence in the study area during the study period
- Agree to come to study clinic for any illness
- Agree to avoid medications outside the study, even herbal medication
Who cannot join
- Another child from household already randomly selected for recruitment
- Not able or does not provide informed consent
- Need for emergency intervention
- Known history of chronic illness requiring regular specialty care including diabetes mellitus, cancer, or Stage 3 or 4 HIV/AIDS
- Contraindications to artemether-lumefantrine (AL) including history of allergic reaction, weight under 5 kg
- Participation in another active/ongoing intervention trial
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Child Health and Infection With Low Density (CHILD) Malaria, a Randomized Controlled Trial to Assess the Long-term Health and Socioeconomic Impact of Interventions Targeting Low-density Malaria Infection (LMI) Among Children in Tanzania
This trial will assess the long-term health and socioeconomic impact of interventions targeting low-density malaria infection (LMI) among children in Tanzania
Read the detailed description
This is a 3-arm open-label randomized control trial of 600 children aged 6 months to 10 years in Tanzania, where transmission is low and a high proportion of infections are low-density. Standard of care based on passive case detection (PCD) using rapid diagnostic test (control arm) will be compared to two different approaches to detect and treat P. falciparum LMI: active case detection using molecular testing (ACDm) and PCD using molecular testing (PCDm). Aims are:
- To assess the impact of standard PCD plus ACDm vs standard PCD on long-term child health
- To assess the impact of PCDm vs standard PCD on long-term child health
- To evaluate the cost-effectiveness of ACDm and PCDm
- Conditions
- Malaria,Falciparum, Malaria
- Being tested
- Active case detection using molecular testing (ACDm), Passive case detection using molecular testing (PCDm), Control (standard of care)
- Keywords
- malaria, child health, chronic infection, subclinical infection, patent infection, subpatent infection, active case detection, passive case detection, fever case management
- Medical subject headings
- Malaria, Falciparum, Malaria, Persistent Infection, Asymptomatic Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Active case detection using molecular testing (ACDm)Other
In the ACDm arm, children will receive ACD using RDT and qPCR 3x yearly with treatment using artemether-lumefantrine (AL) if RDT or qPCR positive. With fevers, participants will receive standard PCD using RDT.
Passive case detection using molecular testing (PCDm)Other
With fevers, participants will receive PCDm, in which qPCR will be done in RDT negatives with treatment using AL if positive.
Control (standard of care)Other
With fevers, participants will receive standard PCD using RDT with treatment using AL if positive.
| Study group | Role | What they receive |
|---|---|---|
| Active Case Detection using molecular testing (ACDm) | Experimental | Per standard of care, children will receive passive case detection (PCD) using rapid diagnostic test (RDT) if they present with fever.
Children will receive malaria active case detection (ACD) using RDT and qPCR (quantitative polymerase chain reaction) three times yearly with treatment using artemether-lumefantrine (AL) if RDT or qPCR positive. Receives: Other: Active case detection using molecular testing (ACDm) |
| Passive Case Detection using molecular testing (PCDm) | Experimental | Children who present with fever will receive PCD using RDT and qPCR with treatment using AL if RDT or qPCR positive.
Per standard of care, children will not receive malaria ACD. Receives: Other: Passive case detection using molecular testing (PCDm) |
| Standard passive case detection (PCD) | Active comparator | Per standard of care, children will receive PCD using RDT.
Per standard of care, children will not receive malaria ACD. Receives: Other: Control (standard of care) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of all-cause sick visits
Number of sick visits to health facility per person time, excluding planned admissions for medical care, elective surgery, and trauma.
Measured: 24-30 months from enrollment
Secondary outcomes (31)
Prevalence of anemia
Proportion of routine Hb measurements that are low (<11 g/dL) or moderate-severe low (<8 g/dL)
Measured: 24-30 months from enrollment
Prevalence of underweight status
Prevalence of underweight status will be defined as the percentage of participants with low weight for age z-scores of less than -2. The World Health Organization (WHO) anthropometric indices will be utilized for standards.
Measured: 24-30 months from enrollment
Prevalence of stunting
Prevalence of stunting will be defined as the percentage of participants with low height for age z-scores of less than -2. The World Health Organization (WHO) anthropometric indices will be utilized for standards.
Measured: 24-30 months from enrollment
Prevalence of wasting
Prevalence of wasting will be defined as the percentage of participants with low weight for height z-scores of less than -2. The World Health Organization (WHO) anthropometric indices will be utilized for standards.
Measured: 24-30 months from enrollment
Prevalence of malnutrition
Prevalence of malnutrition will be defined as the percentage of participants with a z-score of -3 to -2 indicating moderate malnutrition or a z-score of less than -3 indicating severe malnutrition in any of the following: weight for age, height for age, or weight for height.
Measured: 24-30 months from enrollment
Prevalence of vomiting following administration of study drugs
Vomiting immediately or within 30minutes following administration of study drugs and measures of non-adherence.
Measured: 24-30 months from enrollment
All-cause fever episodes
Number of fever episodes (reported fever in the past 48hrs and/or axillary temperature of ≥37.5°C) per person time
Measured: 24-30 months from enrollment
Incidence of clinical symptoms
Number of days with overall symptoms reported as moderate (≥3 on a 5-point scale) per person time
Measured: 24-30 months from enrollment
Incidence of clinical malaria
New episodes of positive malaria test (with fever or other clinical symptoms) per person time
Measured: 24-30 months from enrollment
Proportion of fever episodes with clinical failure
Proportion of fever episodes that lead to clinical failure, defined as persistent or worsening symptoms assessed 7 and 28 days after initial evaluation.
Measured: 24-30 months from enrollment
Prevalence of parasitemia
Proportion of routine samples with parasites detected by microscopy or quantitative polymerase chain reaction (qPCR).
Measured: 24-30 months from enrollment
Incidence in antibiotics prescribed
Number of antibiotic regimens prescribed per person time
Measured: 24-30 months from enrollment
Cognitive ability among children 0-3.4 years of age on the Global Scales of Early Development (GSED)
GSED is a validated instrument that measures population-level early childhood development. The tool measures children's early skills and behaviors in four primary domains: motor, cognitive, language, and social-emotional development.Measures will be normalized within our sample to mean 0 and standard deviation 1, with higher scores indicating better test performance.
Measured: 24-30 months from enrollment
Cognitive ability among children 3.5-5 years of age on the International Development and Early Learning Assessment (IDELA)
The IDELA is a validated, global tool that uses direct child assessment to measure early learning and development across 4 core domains (Emergent Literacy, Emergent Numeracy, Motor, Social-emotional). Scores range from 0-100% as a percentage of correct tasks averaged across the 4 domains. Measures will be normalized within our sample to mean 0 and standard deviation 1, with higher scores indicating better test performance.
Measured: 24-30 months from enrollment
Cognitive ability among children 6-12 years of age on the East Africa Neurodevelopment Assessment Tool
The East African Neurodevelopment Assessment Tool is a locally adapted modification of the Kaufman Brief Intelligence Test 2nd Ed. The test assesses 3 core metrics including general intelligence, executive function, literacy skills - in addition to behavioral and emotional development. Measures will be normalized within our sample to mean 0 and standard deviation 1, with higher scores indicating better test performance.
Measured: 24-30 months from enrollment
Sustained attention among children 5-8 years of age on the Pencil Tapping Test
The pencil tapping test is one of the tasks in the Preschool Self-Regulation Assessment (PSRA) and is used to assess inhibitory control in younger children. The child and an assessor have pencils, and child is instructed to tap one/two times(s) depending on what assessor does, with the number of correct responses scored. Measures will be normalized within our sample to mean 0 and standard deviation 1, with higher scores indicating better test performance.
Measured: 24-30 months from enrollment
Sustained attention among children 9-12 years of age on the Code Transmission Test, a local adaptation of the Test of Everyday Attention for Children(TEA-Ch)
Code transmission test is a sub-test of Test of Everyday Attention for Children (TEA-Ch) used for assessment of sustained attention in children. In the test, the child must remember spoken digits, and remember the digit that comes before sequence of numbers. Child is scored on completed and correct answers. Measures will be normalized within our sample to mean 0 and standard deviation 1, with higher scores indicating better test performance.
Measured: 24-30 months from enrollment
Incidence of school absenteeism
The number of days of school absenteeism for any reason including illness.
Measured: 24-30 months from enrollment
School performance
School performance will be defined as the incidence of school advancement to the next grade.
Measured: 24-30 months from enrollment
Socioeconomic costs to participant
Estimated long-term income loss due to impaired early childhood development
Measured: 24-30 months from enrollment
Socioeconomic costs to family
Total caregiver-reported costs of sick visits and transport to sick visits plus estimated loss of income from number of days of caregiver work absenteeism.
Measured: 24-30 months from enrollment
Socioeconomic costs to health system
Estimated costs of testing and treatment for caregiver-reported number of sick visits.
Measured: 24-30 months from enrollment
Cost effectiveness
Cost per outcome averted (e.g., per sick visit averted, per disability adjusted life years (DALYs), and per economic dollar saved, etc.)
Measured: 24-30 months from enrollment
Prevalence of systemic inflammation
Proportion of sick visits with elevated elevated C-reactive pep-tide (CRP)
Measured: 24-30 months from enrollment
Proportion with antimalarial antibodies against P.falciparum
Percentage of patients with antimalarial antibodies
Measured: 24-30 months from enrollment
Proportion with biomarkers of inflammation
Percentage of patients with elevated cytokines
Measured: 24-30 months from enrollment
Proportion with general antibody responses to vaccines
Percentage of patients with vaccine antibodies
Measured: 24-30 months from enrollment
Proportion with general antibody responses to common pathogens
Percentage of patients with common pathogen antibodies
Measured: 24-30 months from enrollment
Incidence of adverse events (AEs)
Number of AEs per person time. AEs will be considered as any grade 3-4 AE or serious adverse event (SAE); individual AEs; or AEs related to study drugs.
Measured: 24-30 months from enrollment
Incidence of wasting
Incidence proportion of wasting will be defined for each age range of measurement. It is defined as the proportion of children not wasted at the start of the period who became wasted during the age period (the proportion of children who had the onset of new episodes during the period). Incident wasting episodes are defined as a change in weight-for-length z-scores from above -2 Z in the prior measurement to below -2 Z in the current measurement. We will define incident severe wasting analogously using a -3 Z cutoff. We will assume a 60-day washout period before a new wasting episode could occur.
Measured: 24-30 months from enrollment
Incidence of stunting
Incidence proportion of stunting will be defined for each age range of measurement. It is defined as the proportion of children not stunted at the start of the period who became stunted during the age period. Incident stunting episodes will be defined as a change in length-for-age z-scores from above -2 Z in the prior measurement to below -2 Z in the current measurement. We will define incident severe stunting analogously using a -3 Z cutoff.
Measured: 24-30 months from enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Oct 2022
- Study start18 Jul 2023
- Primary completion28 Nov 2025
- Study completion28 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Malaria,FalciparumStudies of the same condition, open and under way.
- More trials run by University of California, San FranciscoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Individual randomized controlled trial
- Masking
- None (open label)
- Enrolment
- 600 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of California, San Francisco
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID), Ifakara Health Institute, Swiss Tropical & Public Health Institute, Stanford University, Chan Zuckerberg Biohub
- Responsible party
- Sponsor
- Investigators
- Michelle Hsiang, MD, MSc, Principal investigator, University of California, San FranciscoAlly Olotu, MD, PhD, Principal investigator, Ifakara Health Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05567016
- Sponsor's protocol ID
- DMID protocol 21-0046
- Other IDs
- U01AI155315
- Status last verified
- Jan 2026
- First submitted
- 30 Sep 2022
- Last updated
- 29 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Summary results information will be submitted to ClinicalTrials.gov within 12 months of completion of follow-up of all study participants. After completion of the clinical trial, un-blinding will be performed, and results will be disseminated widely by presentation at international scientific meetings, in reports and policy meetings for local, regional, and global stakeholders, and in publications in peer-reviewed journals. Upon completion of planned analyses and publication of the main trial results, data will be made available for research purposes to other individuals in the scientific community upon request to the PI and Consortium PIs. Informed consent documents for the study will include a specific statement relating to posting and sharing of study information at ClinicalTrials.gov, and in presentations, reports, and publications, and that no individual identities will ever be used in these materials and forums.
Publications
Jebiwott S, Gutapaka N, Sumari D, Loss G, Athuman T, Nyandele JP, Cummins H, Chemba M, Benjamin-Chung J, Gangar P, Wu X, Smith J, Chen I, Dorsey G, Fink G, Olotu A, Hsiang M. Child Health and Infection with Low Density (CHILD) malaria: a protocol for a randomised controlled trial to assess the long-term health and socioeconomic impacts of testing and treating low-density malaria infection among children in Tanzania. BMJ Open. 2024 Mar 27;14(3):e082227. doi: 10.1136/bmjopen-2023-082227.
PubMed 38538037
Study at a glance
From the registry record, last updated by the sponsor on 29 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Child Health and Infection With Low Density (CHILD) Malaria, a Randomized Controlled Trial to Assess the Long-term Health and Socioeconomic Impact of Interventions Targeting Low-density Malaria Infection (LMI) Among Children in Tanzania
- ClinicalTrials.gov ID
- NCT05567016
- Acronym / sponsor ID
- DMID protocol 21-0046
- Conditions
- Malaria,Falciparum, Malaria
- Keywords
- malaria, child health, chronic infection, subclinical infection, patent infection, subpatent infection, active case detection, passive case detection
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 600 participants (actual)
- Lead sponsor
- University of California, San FranciscoUniversity, hospital or other
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID), Ifakara Health Institute, Swiss Tropical & Public Health Institute, Stanford University, Chan Zuckerberg Biohub
- Study start
- 18 Jul 2023 (actual)
- Primary completion
- 28 Nov 2025 (actual)
- Study completion
- 28 Nov 2025 (actual)
- First posted
- 5 Oct 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This trial will assess the long-term health and socioeconomic impact of interventions targeting low-density malaria infection (LMI) among children in Tanzania
Detailed description
This is a 3-arm open-label randomized control trial of 600 children aged 6 months to 10 years in Tanzania, where transmission is low and a high proportion of infections are low-density. Standard of care based on passive case detection (PCD) using rapid diagnostic test (control arm) will be compared to two different approaches to detect and treat P. falciparum LMI: active case detection using molecular testing (ACDm) and PCD using molecular testing (PCDm). Aims are:
- To assess the impact of standard PCD plus ACDm vs standard PCD on long-term child health
- To assess the impact of PCDm vs standard PCD on long-term child health
- To evaluate the cost-effectiveness of ACDm and PCDm
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- Individual randomized controlled trial
| Arm | Type | Receives |
|---|---|---|
| Active Case Detection using molecular testing (ACDm) | Experimental | Other: Active case detection using molecular testing (ACDm)Per standard of care, children will receive passive case detection (PCD) using rapid diagnostic test (RDT) if they present with fever. Children will receive malaria active case detection (ACD) using RDT and qPCR (quantitative polymerase chain reaction) three times yearly with treatment using artemether-lumefantrine (AL) if RDT or qPCR positive. |
| Passive Case Detection using molecular testing (PCDm) | Experimental | Other: Passive case detection using molecular testing (PCDm)Children who present with fever will receive PCD using RDT and qPCR with treatment using AL if RDT or qPCR positive. Per standard of care, children will not receive malaria ACD. |
| Standard passive case detection (PCD) | Active comparator | Other: Control (standard of care)Per standard of care, children will receive PCD using RDT. Per standard of care, children will not receive malaria ACD. |
Who may qualify
- Ages
- 6 months to 10 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- 6 months to 10 years of age of age at enrollment
- Primary residence in the study area during the study period
- Agree to come to study clinic for any illness
- Agree to avoid medications outside the study, even herbal medication
Key exclusion criteria (6 listed)
- Another child from household already randomly selected for recruitment
- Not able or does not provide informed consent
- Need for emergency intervention
- Known history of chronic illness requiring regular specialty care including diabetes mellitus, cancer, or Stage 3 or 4 HIV/AIDS
- Contraindications to artemether-lumefantrine (AL) including history of allergic reaction, weight under 5 kg
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Active case detection using molecular testing (ACDm)In the ACDm arm, children will receive ACD using RDT and qPCR 3x yearly with treatment using artemether-lumefantrine (AL) if RDT or qPCR positive. With fevers, participants will receive standard PCD using RDT. | Other | Active Case Detection using molecular testing (ACDm) |
| Passive case detection using molecular testing (PCDm)With fevers, participants will receive PCDm, in which qPCR will be done in RDT negatives with treatment using AL if positive. | Other | Passive Case Detection using molecular testing (PCDm) |
| Control (standard of care)With fevers, participants will receive standard PCD using RDT with treatment using AL if positive. | Other | Standard passive case detection (PCD) |
Primary outcome
Incidence of all-cause sick visits
Time frame: 24-30 months from enrollment
Number of sick visits to health facility per person time, excluding planned admissions for medical care, elective surgery, and trauma.
31 secondary outcomes
Prevalence of anemia
Time frame: 24-30 months from enrollment
Prevalence of underweight status
Time frame: 24-30 months from enrollment
Prevalence of stunting
Time frame: 24-30 months from enrollment
Prevalence of wasting
Time frame: 24-30 months from enrollment
Prevalence of malnutrition
Time frame: 24-30 months from enrollment
Prevalence of vomiting following administration of study drugs
Time frame: 24-30 months from enrollment
All-cause fever episodes
Time frame: 24-30 months from enrollment
Incidence of clinical symptoms
Time frame: 24-30 months from enrollment
Incidence of clinical malaria
Time frame: 24-30 months from enrollment
Proportion of fever episodes with clinical failure
Time frame: 24-30 months from enrollment
Prevalence of parasitemia
Time frame: 24-30 months from enrollment
Incidence in antibiotics prescribed
Time frame: 24-30 months from enrollment
Cognitive ability among children 0-3.4 years of age on the Global Scales of Early Development (GSED)
Time frame: 24-30 months from enrollment
Cognitive ability among children 3.5-5 years of age on the International Development and Early Learning Assessment (IDELA)
Time frame: 24-30 months from enrollment
Cognitive ability among children 6-12 years of age on the East Africa Neurodevelopment Assessment Tool
Time frame: 24-30 months from enrollment
Sustained attention among children 5-8 years of age on the Pencil Tapping Test
Time frame: 24-30 months from enrollment
Sustained attention among children 9-12 years of age on the Code Transmission Test, a local adaptation of the Test of Everyday Attention for Children(TEA-Ch)
Time frame: 24-30 months from enrollment
Incidence of school absenteeism
Time frame: 24-30 months from enrollment
School performance
Time frame: 24-30 months from enrollment
Socioeconomic costs to participant
Time frame: 24-30 months from enrollment
Socioeconomic costs to family
Time frame: 24-30 months from enrollment
Socioeconomic costs to health system
Time frame: 24-30 months from enrollment
Cost effectiveness
Time frame: 24-30 months from enrollment
Prevalence of systemic inflammation
Time frame: 24-30 months from enrollment
Proportion with antimalarial antibodies against P.falciparum
Time frame: 24-30 months from enrollment
Proportion with biomarkers of inflammation
Time frame: 24-30 months from enrollment
Proportion with general antibody responses to vaccines
Time frame: 24-30 months from enrollment
Proportion with general antibody responses to common pathogens
Time frame: 24-30 months from enrollment
Incidence of adverse events (AEs)
Time frame: 24-30 months from enrollment
Incidence of wasting
Time frame: 24-30 months from enrollment
Incidence of stunting
Time frame: 24-30 months from enrollment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jan 2026.
- Derived from this study: PubMed 38538037Jebiwott S, Gutapaka N, Sumari D, Loss G, Athuman T, Nyandele JP, Cummins H, Chemba M, Benjamin-Chung J, Gangar P, Wu X, Smith J, Chen I, Dorsey G, Fink G, Olotu A, Hsiang M. Child Health and Infection with Low Density (CHILD) malaria: a protocol for a randomised controlled trial to assess the long-term health and socioeconomic impacts of testing and treating low-density malaria infection among children in Tanzania. BMJ Open. 2024 Mar 27;14(3):e082227. doi: 10.1136/bmjopen-2023-082227.
- Individual participant dataSharing planned: Yes. Summary results information will be submitted to ClinicalTrials.gov within 12 months of completion of follow-up of all study participants. After completion of the clinical trial, un-blinding will be performed, and results will be disseminated widely by presentation at international scientific meetings, in reports and policy meetings for local, regional, and global stakeholders, and in publications in peer-reviewed journals. Upon completion of planned analyses and publication of the main trial results, data will be made available for research purposes to other individuals in the scientific community upon request to the PI and Consortium PIs. Informed consent documents for the study will include a specific statement relating to posting and sharing of study information at ClinicalTrials.gov, and in presentations, reports, and publications, and that no individual identities will ever be used in these materials and forums.
Related trials for Malaria,Falciparum
RecruitingPhase 1
Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults
Malaria Falciparum
Not yet recruiting
Three-arm Cluster Randomised Control Trial Evaluation of Guardian Spatial Emanator as a Complimentary Vector Control Tool in Papua New Guinea
Malaria
Active, not recruitingPhase 4
Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics
Malaria,Falciparum, Malaria in Pregnancy
Not yet recruiting
Permethrin-Treated Baby Wraps for Malaria Prevention in Refugee Settings
Malaria (Plasmodium Falciparum), Malaria Incidence
RecruitingPhase 1/2
DON in Pediatric Cerebral Malaria
Malaria, Cerebral
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michelle Hsiang, MD, MSc principal investigator
University of California, San Francisco
Ally Olotu, MD, PhD principal investigator
Ifakara Health Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Active case detection using molecular testing (ACDm) and Passive case detection using molecular testing (PCDm) in people with Malaria,Falciparum and Malaria, run by University of California, San Francisco at 1 site in Tanzania.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Tanzania. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of all-cause sick visits (time frame: 24-30 months from enrollment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05567016, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jan 2026.